Company: ZLAB
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001628280-25-008409
Chunk: 21

Company: Zai Lab Ltd
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 21
---
15,137)(14,850)(56,403)Other income, net175,300 7,006 3,113 Loss before income tax and share of loss from equity method investment(257,103)(334,620)(443,065)Income tax expense11— — — Share of loss from equity method investment— — (221)Net loss(257,103)(334,620)(443,286)Loss per share — basic and diluted14(0.26)(0.35)(0.46)Weighted-average shares used in calculating net loss per ordinary share — basic and diluted989,477,730 966,394,130 958,067,140 

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Zai Lab Limited 

Consolidated Statements of Comprehensive Loss 

(in thousands of $) 

Year Ended December 31,202420232022Net loss(257,103)(334,620)(443,286)Other comprehensive income, net of tax of nil:Foreign currency translation adjustments12,889 11,941 49,330 Comprehensive loss(244,214)(322,679)(393,956)

The accompanying notes are an integral part of these consolidated financial statements.

F-7

Zai Lab Limited 

Consolidated Statements of Shareholders’ Equity 

(in thousands of $, except for number of shares)

Ordinary sharesAdditionalpaidin capitalAccumulateddeficit Accumulatedothercomprehensiveincome (loss) Treasury Stock Number ofSharesAmountNumber ofShares Amount Total Balance at January 1, 2022955,363,9806 2,825,948 (1,418,074)(23,645)(382,930)(4,279)1,379,956 Issuance of ordinary shares upon vesting of restricted shares1,940,6800 0 — — —— — Exercise of share options5,151,1900 5,870 — — —— 5,870 Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation— — — — — (1,853,350)(7,577)(7,577)Share-based compensation— — 61,302 — — —— 61,302 Net loss— — — (443,286)— —— (443,286)Foreign currency translation